AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-3…
Biotechnology
US, San Diego [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
AnaptysBio, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDAnaptysBio, Inc. can't present revenue by segment